Table 2.
D1R antagonism increased omissions when infused in the NAcC.
| Region | Dose | Omissions | Latency to collect | Latency to respond | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Early | Mid | Late | Early | Mid | Late | Early | Mid | Late | ||
| A) Raclopride | ||||||||||
| DMS | Veh | 1.43 ± 0.43 | 1.33 ± 0.30 | 0.23 ± 0.12 | 3.06 ± 0.03 | 3.04 ± 0.05 | 2.91 ± 0.03 | 3.00 ± 0.02 | 3.00 ± 0.02 | 3.01 ± 0.02 |
| 0.1 | 1.00 ± 0.39 | 1.20 ± 0.37 | 0.43 ± 0.18 | 3.12 ± 0.05a | 3.08 ± 0.04a | 2.95 ± 0.03a | 3.00 ± 0.02 | 3.00 ± 0.02 | 3.00 ± 0.02 | |
| 1 | 2.63 ± 0.83 | 2.83 ± 0.74 | 0.63 ± 0.22 | 3.23 ± 0.05b | 3.10 ± 0.03b | 3.01 ± 0.04b | 3.07 ± 0.02 | 3.04 ± 0.02 | 3.06 ± 0.02 | |
| DLS | Veh | 0.60 ± 0.40 | 0.30 ± 0.21 | 0.50 ± 0.50 | 3.01 ± 0.04 | 2.93 ± 0.04 | 3.01 ± 0.09 | 3.02 ± 0.07 | 2.98 ± 0.02 | 2.99 ± 0.04 |
| 0.1 | 0.50 ± 0.50 | 0.40 ± 0.13 | 0.10 ± 0 13 | 3.01 ± 0.06 | 2.96 ± 0.06 | 2.89 ± 0.07 | 2.99 ± 0.02 | 2.98 ± 0.02 | 2.96 ± 0.02 | |
| 1 | 0.90 ± 0.50 | 0.20 ± 0.13 | 0.20 ± 0.13 | 3.07 ± 0.06 | 3.03 ± 0.06 | 2.92 ± 0.07 | 3.04 ± 0.02 | 3.01 ± 0.02 | 2.99 ± 0.02 | |
| NAcC | Veh | 2.91 ± 0.88 | 1.14 ± 0.33 | 0.36 ± 0.14 | 3.22 ± 0.05 | 3.09 ± 0.03 | 3.08 ± 0.04 | 3.08 ± 0.02 | 3.06 ± 0.02 | 3.07 ± 0.02 |
| 0.1 | 2.05 ± 0.64 | 1.41 ± 0.40 | 0.86 ± 0.27 | 3.19 ± 0.06 | 3.09 ± 0.03 | 3.03 ± 0.04 | 3.10 ± 0.03 | 3.08 ± 0.02 | 3.09 ± 0.02 | |
| 1 | 3.68 ± 1.09 | 2.59 ± 0.89 | 0.36 ± 0.14 | 3.24 ± 0.04 | 3.15 ± 0.04 | 3.08 ± 0.50 | 3.13 ± 0.03 | 3.10 ± 0.03 | 3.08 ± 0.02 | |
| NAcS | Veh | 1.00 ± 0.70 | 0.50 ± 027 | 0.10 ± 0.10 | 3.26 ± 0.05 | 3.17 ± 0.04 | 3.08 ± 0.05 | 2.98 ± 0.03 | 2.91 ± 0.03 | 2.90 ± 0.03 |
| 0.1 | 0.30 ± 0.15 | 0.20 ± 0.22 | 0.10 ± 0.10 | 3.21 ± 0.05 | 3.15 ± 0.04 | 3.03 ± 0.05 | 2.90 ± 0.05 | 2.90 ± 0.05 | 2.91 ± 0.04 | |
| 1 | 0.30 ± 0.15 | 0.50 ± 0.22 | 0.10 ± 0.10 | 3.17 ± 0.05 | 3.13 ± 0.04 | 3.04 ± 0.05 | 2.97 ± 0.05 | 2.91 ± 0.05 | 2.91 ± 0.04 | |
| B) SCH23390 | ||||||||||
| DMS | Veh | 1.20 ± 0.54 | 1.56 ± 0.53 | 0.24 ± 0.09 | 3.15 ± 0.03 | 3.08 ± 0.03 | 2.99 ± 0.03 | 3.01 ± 0.02 | 3.00 ± 0.02 | 3.01 ± 0.02 |
| 1 | 1.36 ± 0.55 | 2.00 ± 0.75 | 0.60 ± 0.33 | 3.27 ± 0.05b | 3.23 ± 0.05b | 3.15 ± 0.04b | 3.02 ± 0.02 | 3.02 ± 0.02 | 3.04 ± 0.02 | |
| DLS | Veh | 0.00 ± 0.00 | 0.20 ± 0.20 | 0.00 ± 0.00 | 3.07 ± 0.08 | 3.03 ± 0.07 | 3.15 ± 0.09 | 2.99 ± 0.04 | 3.00 ± 0.05 | 2.99 ± 0.04 |
| 1 | 1.40 ± 1.16 | 0.17 ± 0.17 | 0.00 ± 0.00 | 3.19 ± 0.06 | 3.16 ± 0.06 | 3.17 ± 0.11 | 3.00 ± 0.04 | 3.00 ± 0.03 | 3.02 ± 0.05 | |
| NAcC | Veh | 0.64 ± 0.24 | 1.54 ± 0.71 | 0.69 ± 0.47 | 3.23 ± 0.09 | 3.12 ± 0.07 | 3.06 ± 0.06 | 3.04 ± 0.03 | 3.01 ± 0.03 | 3.05 ± 0.03 |
| 1 | 30.08 ± 10.22c | 8.08 ± 2.63 | 1.92 ± 0.74 | 3.79 ± 0.07b | 3.57 ± 0.07b | 3.54 ± 0.10b | 3.23 ± 0.04b | 3.22 ± 0.05b | 3.25 ± 0.03b | |
| NAcS | Veh | 0.13 ± 0.13 | 0.50 ± 0.38 | 0.00 ± 0.00 | 3.09 ± 0.04 | 3.05 ± 0.04 | 3.00 ± 0.05 | 2.99 ± 0.04 | 2.97 ± 0.04 | 2.97 ± 0.05 |
| 1 | 0.00 ± 0.00 | 1.00 ± 0.42 | 0.88 ± 0.30 | 3.47 ± 0.07b | 3.34 ± 0.06b | 3.32 ± 0.06b | 3.01 ± 0.04b | 3.01 ± 0.04b | 3.07 ± 0.04b | |
Effects of microinfusions of the A) D2R antagonist, raclopride (0, 0.1, 1 µg/µl) and B) D1R antagonist, SCH23390 (0, 1 µg/µl), in the DMS, DLS, NAcC and NAcS during the different phases of visual reversal learning (early, mid and late) as omissions, latencies to collect the reward and latencies to respond. Data are mean ± SEM. Latencies are presented as log-transformed values
ap < 0.01 vs vehicle treatment, Tukey post hoc after significant Dose × Region interaction
bp < 0.001 vs vehicle treatment, Tukey post hoc after significant Dose × Region interaction
cp < 0.001 after significant Dose × Phase × Region interaction